Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Acne Vulgaris
Interventions: IDP-110, Clindamycin, Benzoyl peroxide, Vehicle; Drug
Lead sponsor: Dow Pharmaceutical Sciences; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 1,399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 33
States / cities: Hot Springs, Arkansas • New Haven, Connecticut • Hockessin, Delaware + 28 more

Conditions: Pruritus
Interventions: Biopsy, Blood; Procedure
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NODULOCYSTIC ACNE
Interventions: Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets; Drug
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more

Conditions: Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Interventions: MORAb-066; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Dermatitis Atopic
Interventions: dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 14 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • New York, New York

Conditions: Breast Neoplasms
Interventions: accelerated partial breast irradiation; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Raloxifene - Usual, Raloxifene - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 24 Years to 64 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Breast Cancer
Interventions: 12-week Intervention Period, 12-week Observation Period; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Breast Neoplasms, Obesity
Interventions: Biopsy, Blood draw, Mammogram, MRI; Procedure
Lead sponsor: Tarah J Ballinger, MD; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Angioneurotic Edema
Interventions: HOE-140, Placebo; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Palmoplantar Pustulosis
Interventions: Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • Columbia, Missouri • East Windsor, New Jersey + 3 more

Conditions: Advanced Melanoma, Triple-Negative Breast Cancer
Interventions: Imprime PGG, Pembrolizumab; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Avondale, Arizona • Santa Monica, California • Aurora, Colorado + 7 more

Conditions: Breast Cancer
Interventions: Exercise Intervention; Other
Lead sponsor: San Diego Biomedical Research Institute; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Flt3L, Radiation, Poly ICLC; Drug · Radiation
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus (Sle)
Interventions: Nicotinamide Riboside; Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Behcet Syndrome
Interventions: Apremilast (CC-10004), Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Psychosocial
Interventions: Phenomenological Interviews, Quantitative Interviews; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Houston, Texas

Conditions: Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions: Observation; Other
Lead sponsor: Insel Gruppe AG, University Hospital Bern; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Thoracic Cancer, Left Sided Breast Cancer
Interventions: [1-13C]pyruvate along with MRI imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Fatigue
Interventions: Walk With Ease Arm A; Behavioral
Lead sponsor: The West Clinic, Memphis; Industry
Eligibility: 65 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Memphis, Tennessee

Conditions: Skin Cancer, Non-Melanoma
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Rheumatoid Arthritis
Interventions: BMS-582949 and Methotrexate; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Palm Desert, California • Upland, California • Delray Beach, Florida + 4 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions: doxycycline, vancomycin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Finasteride Treatment of Severe Nodulocystic Acne

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

HIIT Following Breast Cancer Chemotherapy

Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer

Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

Exercise Study for Breast Cancer Survivors

Vaccination With Flt3L, Radiation, and Poly-ICLC

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Effects of Cancer Symptoms on Caregivers

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity

The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)